Dataset Information
Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.
Ontology highlight
ABSTRACT: Introduction
Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue.Methods
In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials.Results
Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14-9.45.Conclusion
Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID-19, especially in the light of unproved clinical benefit.
SUBMITTER: Maraolo AE
PROVIDER: S-EPMC7753686 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature
Publications
Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.
Immunity, inflammation and disease 20201126 1
<h4>Introduction</h4>Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue.<h4>Methods</h4>In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials.<h4>Results</h4>Five studies investigating 2291 subjects were ...[more]